trending Market Intelligence /marketintelligence/en/news-insights/trending/yk3spfpbfpn3sg4hn-w5ow2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Provention Bio plans $50M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Provention Bio plans $50M IPO

Oldwick, N.J.-based Provention Bio Inc. is looking to raise up to $50 million in its IPO.

The biopharmaceutical company plans to list its shares on the Nasdaq Capital Market under the symbol PRVB. It also intends to grant underwriters an option to buy additional shares in the offering.

Provention Bio is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases.

Net proceeds from the IPO will be used to fund the ongoing clinical development of its drugs indicated to treat acute coxsackie B virus and autoimmune diseases including Crohn's disease, ulcerative colitis, lupus and type 1 diabetes.

MDB Capital Group LLC is acting as the underwriter for the IPO.